Container Closure Integrity

What Is Container Closure Integrity?

The container closure integrity test (CCIT) verifies that a sterile product's packaging system maintains its barrier function against microbial ingress and content loss. USP <1207> divides methods into deterministic and probabilistic; deterministic methods are preferred because they rely on a measurable physical quantity.

Purpose of Container Closure Integrity

The purpose is to show the product will remain sterile over its shelf life. In sterile products, packaging integrity is as critical a safety component as sterilisation itself.

Which Products Is Container Closure Integrity Applied To?

Injectable vials and ampoules
Pre-filled syringes
Lyophilised products
Infusion bags
Eye-drop packaging

In Which Sectors Is Container Closure Integrity Used?

PharmaceuticalsBiotechnologyMedical DevicePackaging

Standards Related to Container Closure Integrity

USP <1207> (package integrity evaluation — sterile products)
ASTM F2338 (leak detection by vacuum decay method)
ASTM F1929 (dye penetration)
ASTM F3287 (integrity via headspace gas analysis)
TS EN ISO 11607-1 (sterile barrier systems)

Container Closure Integrity Conditions

Method type: Deterministic (vacuum decay, helium, high-voltage, headspace) or probabilistic (dye ingress, microbial immersion)
Sensitivity: The smallest leak size the method can detect is determined and reported
Verification: The method is verified with artificially defective specimens of known size

Equipment for Container Closure Integrity

Vacuum decay test system
Helium leak detector
High-voltage leak detector (HVLD)
Headspace laser gas analysis system
Positive control (artificially defective) specimen sets

Sample Requirements for Container Closure Integrity

Specimens filled and closed under real manufacturing conditions
Positive control specimens of known defect size for method verification
Packaging components and closure parameters must be provided
The number of specimens is determined by the statistical sampling plan

Duration of Container Closure Integrity

A single measurement with deterministic methods is quick. Duration is set by the method verification study and periodic testing tied to the stability programme.

Container Closure Integrity Procedure

1The packaging system and critical leak paths are assessed.
2A suitable method is selected and justified.
3The method is verified with positive controls of known defect size.
4Specimens are tested.
5Results are compared against the acceptance criteria.
6Periodic testing is performed over the stability programme if required.

Container Closure Integrity Acceptance Criteria

The acceptance criterion is no leak detected at the verified sensitivity of the chosen method. USP <1207> defines the concept of the maximum leak size that prevents microbial ingress; the applicable threshold for your product is set based on the packaging system and risk assessment.

Evaluation of Results

The method choice determines what the result means: probabilistic methods such as dye ingress depend on the operator and conditions, and regulatory authorities prefer deterministic methods. The method's sensitivity must also match the packaging system's critical leak size.

Container Closure Integrity Report

Packaging system and component identification
Method selected and its justification
Method verification results and sensitivity
Number of specimens and test results
Acceptance criterion and assessment

Accreditation

EUROLAB holds internationally recognised accreditation obtained from accreditation bodies party to the IAF and ILAC multilateral recognition arrangements, under ISO/IEC 17025 for laboratory testing, ISO/IEC 17020 for inspection and surveillance, and ISO/IEC 17021-1 and ISO/IEC 17065 for system and product certification. This chain ensures the reports and certificates issued are accepted worldwide.

Whether this test can be offered within accredited scope depends on your product and the standard applied; since accreditation is method-based, the scope is confirmed in writing at the quotation stage.

Scope and authorisations

Related Regulations

2001/83/EC Directive on Medicinal Products for Human Use
GMP Annex 1 (manufacture of sterile medicinal products)
(EU) 2017/745 Medical Device Regulation

Pharmaceutical Analysis — What Does This Testing Field Cover?

The section below describes the field that the Container Closure Integrity test belongs to; the conditions and acceptance criteria of this particular test are given in the sections above. The scope specific to your product is confirmed in writing at the quotation stage.

Pharmaceutical analysis determines the identity, purity, quantity and behaviour of an active substance and of the finished product. What sets this family apart is that the methods are largely defined in PHARMACOPOEIAS: the European Pharmacopoeia (Ph. Eur.) and the United States Pharmacopeia (USP) give both the method and the acceptance framework together.

The binding nature of the pharmacopoeial method shapes how the field works. In other sectors a laboratory can choose a suitable method, whereas here the method in the monograph governs; if an alternative method is to be used, its equivalence must be demonstrated. This is what makes results comparable worldwide.

Analyses are carried out in several groups. Identity and assay (HPLC, UV, titration) show what the product is and how much active substance it contains. The impurity profile and residual solvents look for unwanted compounds arising from the manufacturing process. Elemental impurities address metals originating from catalysts and equipment. Dissolution and disintegration behaviour is the most important in vitro indicator of how the drug will be released in the body.

The DISSOLUTION TEST is one of the most critical measurements in the field. It is not enough for a tablet to contain the right amount of active substance; that substance must dissolve at a suitable rate. The dissolution profile is used to assess the effect of formulation changes on bioavailability and holds a central place in generic drug licensing.

METHOD VALIDATION is a mandatory step in this family. If a pharmacopoeial method is used, it is verified that the method works properly under that laboratory's conditions. If an in-house method has been developed, it is validated against parameters such as linearity, precision, accuracy, specificity, limits of detection and quantification, and robustness. A result produced with an unvalidated method cannot be used in a licence dossier.

Stability studies determine shelf life and are the longest-running work in the field. The product is held under defined temperature and humidity conditions, analysed at set intervals, and the results become the basis of the shelf life and storage condition claims. Accelerated conditions give preliminary information but real-time data is what counts.

The microbiological side is a separate body of work: microbial enumeration, testing for specified microorganisms, sterility testing for sterile products and the bacterial endotoxin test. For sterile products, packaging integrity and sterilisation validation also come into play.

Data integrity has moved to the centre of inspections in recent years. It is not enough for the result to be correct; the raw data must be traceable, unalterable and auditable. Validation of electronic record systems has therefore become an inseparable part of analysis.

Method groups in this field

Identity and assay
HPLC, UPLC, UV-Vis spectrophotometry, titration, identity confirmation by FTIR.
Impurities and residues
Related impurities, degradation products, residual solvents (GC headspace), nitrosamine screening.
Elemental impurities
Determination of elemental impurities by ICP-MS and ICP-OES and the associated risk assessment.
Physicochemical
Dissolution and disintegration, hardness, friability, uniformity of dosage units, water content (Karl Fischer), particle size.
Microbiological
Microbial enumeration, specified microorganisms, sterility, bacterial endotoxin, preservative efficacy.
Stability
Real-time and accelerated stability studies; photostability and in-use stability.

Commonly confused in this field

The pharmacopoeial method is binding; an alternative method may be used only by demonstrating its equivalence.
A result produced without method validation cannot be used in a licence dossier.
Accelerated stability does not replace real-time data; shelf life is supported by real-time results.
The dissolution profile is sensitive to apparatus type, agitation rate and medium; the conditions must be complete in the report.
A shortcoming in data integrity produces a non-conformity in an inspection even when the result is correct.
A change of formulation or supplier requires analytical comparison and, where necessary, a new stability study.

Which decisions these results support

The licence dossier and batch release
Determining shelf life and storage conditions
Method transfer and method validation
Incoming raw material acceptance control from suppliers
Assessing the effect of a formulation change on bioequivalence

Related Tests

Frequently Asked Questions About Container Closure Integrity

Is the dye ingress test still accepted?

It can be used, but USP <1207> prefers deterministic methods and clearly states the limitations of probabilistic ones. Choosing and justifying a deterministic method is a safer approach for new products.

Isn't the sterility test enough for sterile products?

No. The sterility test examines a limited number of specimens and does not show the packaging will maintain its barrier function over the shelf life. CCIT answers this second question and is a separate requirement.